Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06456138
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-06-05
Brief Title:
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Sponsor:
Shanghai Chest Hospital
Organization:
Shanghai Chest Hospital
Organization Data
Organization:
Shanghai Chest Hospital
Class:
OTHER
Study ID:
ATT-RAS-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Chest Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Baohui Han
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shanghai Chest Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| BeiGene | INDUSTRY |
| Chia Tai Tianqing Pharmaceutical Group Co Ltd | INDUSTRY |